Trial Profile
A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms GEM-1
- Sponsors Novartis Pharmaceuticals
- 23 May 2018 Results of pooled analysis of the GEM1 and GEM2 studies presented at the 114th International Conference of the American Thoracic Society
- 16 May 2018 According to a Sunovion Pharmaceuticals media release, data from this study will be presented at the American Thoracic Society International Conference 2018.
- 26 May 2016 According to Vectura media release, Seebri™ Neohaler was approved by the FDA in October 2015.